Terumo BCT  

10811 West Collins Avenue
Lakewood,  CO  80215

United States
https://www.terumobct.com/cell-therapy-technologies

• Booth: 1452

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo BCT’s Cell Therapy Technologies business enables researchers, developers and manufacturers to create next-generation cell and gene therapies. We do this through flexible, automated solutions that help meet your evolving needs for reproducibility, quality and scale through the phases of development, from translational research to current good manufacturing practice (cGMP) for commercial manufacturing. One example, the Quantum® Cell Expansion System, automates and optimizes cell culture to meet the needs of a variety of cell types in a consistent, controlled and functionally closed environment. We are also looking further downstream in the process to provide innovative solutions, like the FINIA® Fill and Finish System, to support your needs well into the future.

 Videos

 Press Releases

• New Collaboration with StafaCT Will Optimize Patient Pathways for Cellular Treatments (Sep 12, 2018)

  Lakewood, Colo.—23 February 2018—Terumo BCT announced today that it will be the exclusive distributor for Stafa Cellular Therapy (StafaCT), a U.S.-based software developer. StafaCT software supports healthcare facilities and cell labs as they manage each phase of the cellular therapy process including patient referral, cell collection and processing, transplant and follow-up. Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies.

  Stem cell and immune effector cell transplants are used to treat various blood cancers, immune system disorders and genetic diseases. Given the significance of these treatments to patients, StafaCT and Sarah Cannon Blood Cancer Network co-developed software to manage each phase of the transplant process.

  “Ensuring patients have access to the highest level of care throughout the transplantation process is central to our mission,” said Fred LeMaistre, M.D., Senior Vice President and Physician-in-Chief of Blood Cancers, Sarah Cannon.

  By implementing technologies that support improved patient outcomes and integrated communication for the entire care team, we are setting a new standard in patient care.

  
  Terumo BCT will expand access to StafaCT software to healthcare organizations. The software meets the needs of therapeutic apheresis and cellular therapy procedures, including hematopoietic cellular transplantation and immune effector cellular therapy.

  Offering StafaCT software advances Terumo BCT’s ongoing support of the transplant and apheresis communities. For more than 30 years, Terumo BCT has been an innovator in therapeutic apheresis. The Spectra Optia^® Apheresis System and the COBE^® Spectra Apheresis System are used predominantly throughout the world. Now with StafaCT, Terumo BCT can also streamline workflows and the collection and management of data throughout the continuum of care.

  “Not only does the software from StafaCT ultimately benefit patients, it also helps to ensure the health of the organizations that deliver that care,” says Roy Jones, M.D., Ph.D., former Chair of the Informatics Committee for the American Society for Blood and Marrow Transplantation.

   

  About Terumo BCT
  Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

  About Stafa Cellular Therapy
  Stafa Cellular Therapy (StafaCT) is a software company that specializes in cellular therapy applications, including but not limited to blood and marrow transplants. Its suite of products covers data management, operational workflows, and compliance monitoring for the entire cellular therapy process from the initial referral to infusion and follow up. Formerly the cellular therapy product team at Velos, StafaCT was spun out into its own company in 2015.

  About The Sarah Cannon Blood Cancer Network
  Sarah Cannon brings together physician-led blood cancer programs across the United States and United Kingdom to offer patients convenient access to care including hematopoietic cell transplantation (HCT) and clinical trials. For more information about the Network and Sarah Cannon’s full suite of oncology services, visit sarahcannon.com.

  Media Contact
  Corporate Communications
  Phone: +1.303.542.5396
  Contact Us

• Cognate BioServices and Terumo BCT Announce Collabration Agreement for Innovation (Sep 12, 2018)

  Memphis, TN September 28th, 2018 – Cognate BioServices, a leading contract development

  and manufacturing organization (“CDMO”) in the global cellular therapies industry, today

  announced a collaboration agreement with Terumo BCT, a leading technology provider in the

  cell therapy market. The agreement will provide user insights as Cognate incorporate Terumo

  BCT's existing and future technologies into the company’s Innovation labs.

  Cognate will also serve as a technology reference center for Terumo BCT's devices (including

  the Quantum Cell Expansion System among others) allowing customers to access manufacturing

  guidance and processes and for Cognate to be a technology showcase for closed system

  manufacturing facilities, processes and equipment. Cognates' facilities would also be a beta site

  for new technologies and their use in relevant client processes.

  “Terumo BCT's reputation for bringing automation to the cell therapy industry for apheresis

  and cell processing technologies is outstanding and we are excited to be a center of

  excellence for both our prospective and current clients in the US and abroad. One of our goals

  as a CDMO is to provide the experience and direction for our clients which help to improve

  and expedite processes in all phases. We are also pleased to expand on our existing

  relationship with Terumo BCT to share our innovation team's development and manufacturing

  feedback from clients on current and new technologies.”

  -J. Kelly Ganjei, CEO and Chairman, Cognate BioServices

  About Cognate BioServices

  Cognate BioServices is a fully-integrated contract bioservices organization providing the

  highest level of scientific and management expertise. Cognate provides full development and

  cGMP manufacturing services to companies and institutions engaged in the development and

  manufacture of cell-based products. The combination of highly experienced staff, successful

  track records and cGMP facilities makes Cognate one of the most qualified contract

  manufacturers of cell-based products in the world today. Please visit

  www.cognatebioservices.com for more information

  About Terumo BCT

  Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular

  technologies, is the only company with the unique combination of apheresis collections,

  manual and automated whole blood processing, and pathogen reduction technologies. We

  believe in the potential of blood to do even more for patients than it does today. This belief

  inspires our innovation and strengthens our collaboration with customers.

  Contacts

  Cognate BioServices

  +1.901-541-9800

  press@cognatebioservices.com

  Terumo BCT

  Corporate Communications

  +1.303.542.5396

  press@terumobct.com

• UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies (Oct 10, 2018)

  LAKEWOOD, Colo., USA—9 October 2018— Shanghai UniCAR-Therapy Bio-Medicine

  Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy

  manufacturing process for chimeric antigen receptor (CAR) T-cell therapies. Privately held,

  UniCAR will open their Center of Excellence for Terumo BCT’s technologies in Shanghai in

  November.

  Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy

  technologies. The company provides flexible solutions for CAR T-cell developers and

  manufacturers, including the Quantum® Cell Expansion System, in use at UniCAR today.

  “Compared to the manual method of cell expansion, we save time and increase the quality of

  cells and viruses we grow using the Quantum system,” says Dr. Yu Lei, a pioneer in the gene

  therapy field and Chief Executive Officer, UniCAR. “It only makes sense to share best practices

  and showcase technologies that are driving innovation in our growing industry.”

  In 2018, UniCAR submitted four applications for CAR T-cell drug candidates as investigational

  new drugs (INDs) to China’s National Medical Products Administration (NMPA). UniCAR’s

  advanced CAR T2.0 technologies are designed to reduce the side effects of treatments and

  improve patient outcomes.

  “The science and development in the cell and gene therapy space are rapidly evolving. Both

  UniCAR and Terumo BCT are at the forefront of this quickly changing landscape,” says Cindy

  Ng, Senior Vice President, Global Commercial, Terumo BCT. “Our collaboration has the

  potential to touch many patients’ lives.”

  In addition to automating cell expansion manufacturing with the Quantum system, Terumo BCT

  continues to deliver high-levels of service to support its customer’s innovations. The Finia® Fill

  and Finish System, one of the company’s latest technology in development, is designed to

  automate the final step of cell processing which includes cooling, mixing and aliquoting doses of

  cell therapies. The company’s COBE® Spectra Apheresis System and Spectra Optia® Apheresis

  System are extensively used in the industry to collect high-quality white blood cells—the first

  step in CAR T-cell therapies.

  About UniCAR

  China-based UniCAR Therapy is a pioneer in the industry of cancer immunotherapy. The

  company collaborates with top-ranked hospitals specializing in hematological malignancies,

  including leukemia, lymphoma and multiple myeloma. To date, more than 400 patients have

  benefitted from UniCAR’s immunotherapeutic products. The company holds more than 30

  patents of CAR T-cell technology and is dedicated to the extended application of the next

  generation of CAR T-cell therapies with enhanced efficacy and safety profiles.

  About Terumo BCT

  Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy

  technologies, is the only company with the unique combination of apheresis collections, manual

  and automated whole blood processing, and pathogen reduction technologies. We believe in

  the potential of blood to do even more for patients than it does today. This belief inspires our

  innovation and strengthens our collaboration with customers.

  Media Contacts

  Terumo BCT

  Bradley Hein

  +1.303.542.5396

  press@terumobct.com

  UniCAR Therapy

  Kang Li Qing

  +86 13162512992

  liqing.kang@unicar-therapy.com

 Products